Romidepsin

Romidepsin
Clinical data
Trade names	Istodax
Other names	FK228; FR901228; Istodax
MedlinePlus	a610005
License data	US FDA: Romidepsin;
Routes of; administration	Intravenous infusion
ATC code	L01XH02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Not applicable (IV only)
Protein binding	92–94%
Metabolism	Liver (mostly CYP3A4-mediated)
Elimination half-life	3 hours
Identifiers
	IUPAC name (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone;
CAS Number	128517-07-7 ;
PubChem CID	5352062;
IUPHAR/BPS	7006;
DrugBank	DB06176 ;
ChemSpider	10122002;
UNII	CX3T89XQBK;
ChEBI	CHEBI:61080 ;
ChEMBL	ChEMBL1213490 ;
CompTox Dashboard (EPA)	DTXSID8048579 ;
ECHA InfoCard	100.211.884
Chemical and physical data
Formula	C24H36N4O6S2
Molar mass	540.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C;
	InChI InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1; Key:OHRURASPPZQGQM-GCCNXGTGSA-N;
	(what is this?) (verify)

Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, a part of Celgene.